More on VCRT
Data
Financials
News
Click line-items for a historical chart and %
| Net income (loss) | 956K |
| Depreciation and amortization | 69K |
| Noncash interest imputed upon conversion of debt to equity | 0 |
| Noncash interest and amortization of deferred financing costs | 2.17M |
| Gain on derivative financial instruments | -6.42M |
| Loss from sale of assets | 0 |
| Securities issued for services | 169K |
| Beneficial conversion feature of notes payable | 0 |
| Contributed research and development services | 0 |
| Merger-related costs | 0 |
| Shares in lieu of interest payments | 2K |
| Equity-based compensation | 269K |
| Accounts receivable | -74K |
| Inventory | 35K |
| Prepaid expenses and other assets | -110K |
| Accounts payable and accrued expenses | 1.51M |
| Accrued royalties due to related party | 58K |
| Net cash used in operating activities | -1.36M |
| Purchase of intellectual property | -56K |
| Net proceeds from sale of equipment | 0 |
| Purchase of property and equipment | -31K |
| Net cash used in investing activities | -87K |
| Due to related parties | 1K |
| Proceeds from bank loans | 0 |
| Proceeds from sale of preferred stock | 0 |
| Proceeds from sale of common stock | 0 |
| Proceeds from exercise of warrants | 6K |
| Repayment of notes | 0 |
| Proceeds from bridge loan | 0 |
| Proceeds from sale of notes | 350K |
| Proceeds for stock to be issued | 0 |
| Contributed capital | 0 |
| Net cash provided by financing activities | 357K |
| Net increase (decrease) in cash | -1.09M |
| Cash at beginning of period | 1.12M |
| Cash at end of period | 26K |
| Supplemental cash flow information: | |
| Issuance of previously-subscribed common stock | 0 |
| Conversion of accounts payable to note payable | 0 |
| Repurchase of common stock for cancellation of subscription note receivable | 0 |
| Contributed research and development | 0 |
| Acquisition of intellectual property from related party | 0 |
| Beneficial conversion features for promissory notes | 0 |
| Exercise of warrants to purchase common stock | 0 |
| Cash paid for interest expense | 36K |
| Accrued equity-based compensation | 0 |
| Accrued dividends | 221K |
| Interest on promissory notes paid in common stock | 0 |
| Related-party accrual converted to common stock | 0 |
| Conversion of debt to Series B preferred stock | 0 |
| Conversion of notes to common stock | 394K |
| Accrued expenses paid with notes | 0 |
| Fair value of equity-based derivative financial instruments issued | 0 |
| Fair value of debt-based derivative financial instruments issued | 0 |
| Deferred costs paid with common stock | 34K |
| Amortization of derivative discounts | 498K |
| Supplemental cash flow information: | |
| Warrants issued in connection with notes | 15K |
| Supplemental cash flow information: | |
| Warrants issued in connection with notes | 0 |
| Supplemental cash flow information: | |
| Accrued expenses paid with stock | 0 |
| Supplemental cash flow information: | |
| Accrued expenses paid with stock | 0 |
| Supplemental cash flow information: | |
| Conversion of preferred stock and accrued dividends to common stock | 0 |
| Supplemental cash flow information: | |
| Conversion of preferred stock and accrued dividends to common stock | 0 |
